A RANDOMIZED, CONTROLLED PHARMACOKINETIC (PK) AND PHARMACODYNAMICS (PD) TRIAL OF AMBRISENTAN AFTER FONTAN SURGERY

OBJECTIVES: To determine the pharmacokinetics (PK), pharmacodynamics (PD) and safety of the hepatically-metabolized endothelin receptor antagonist (ERA), ambrisentan in children after Fontan surgery. DESIGN: Prospective, randomized, double blind, placebo controlled PK/PD and safety trial SETTING: Si...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pediatr Crit Care Med
Auteurs principaux: Hill, Kevin D., Maharaj, Anil R., Li, Jennifer S., Thompson, Elizabeth, Barker, Piers C.A., Hornik, Christoph P.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7483887/
https://ncbi.nlm.nih.gov/pubmed/32639468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PCC.0000000000002410
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires